Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan 9;17(1):78.
doi: 10.3390/ijms17010078.

Circulating MicroRNAs as Biomarkers for Sepsis

Fabian Benz  1 , Sanchari Roy  2 , Christian Trautwein  3 , Christoph Roderburg, Tom Luedde
Affiliations
Review

Circulating MicroRNAs as Biomarkers for Sepsis

Fabian Benz et al. Int J Mol Sci. .

Abstract

Sepsis represents a major cause of lethality during intensive care unit (ICU) treatment. Pharmacological treatment strategies for sepsis are still limited and mainly based on the early initiation of antibiotic and supportive treatment. In this context, numerous clinical and serum based markers have been evaluated for the diagnosis, the severity, and the etiology of sepsis. However until now, few of these factors could be translated into clinical use. MicroRNAs (miRNAs) do not encode for proteins but regulate gene expression by inhibiting the translation or transcription of their target mRNAs. Recently it was demonstrated that miRNAs are released into the circulation and that the spectrum of circulating miRNAs might be altered during various pathologic conditions, such as inflammation, infection, and sepsis. By using array- and single PCR-based methods, a variety of deregulated miRNAs, including miR-25, miR-133a, miR-146, miR-150, and miR-223, were described in the context of sepsis. Some of the miRNAs correlated with the disease stage, as well as patients' short and long term prognosis. Here, we summarize the current findings on the role of circulating miRNAs in the diagnosis and staging of sepsis in critically ill patients. We compare data from patients with findings from animal models and, finally, highlight the challenges and drawbacks that currently prevent the use of circulating miRNAs as biomarkers in clinical routine.

Keywords: biomarker; critical illness; miRNA; sepsis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Biogenesis of miRNAs.
Figure 2
Figure 2
Various miRNAs interact with the TLR4 pathway.
Figure 3
Figure 3
Modulation of the pro-inflammatory cytokines TNF-α and IL-6 by various miRNAs and vice versa.
See this image and copyright information in PMC

References

    1. Danai P., Martin G.S. Epidemiology of sepsis: Recent advances. Curr. Infect. Dis. Rep. 2005;7:329–334. doi: 10.1007/s11908-005-0005-1. - DOI - PubMed
    1. Vincent J.L. Management of sepsis in the critically ill patient: Key aspects. Expert Opin. Pharmacother. 2006;7:2037–2045. doi: 10.1517/14656566.7.15.2037. - DOI - PubMed
    1. Angus D.C., van der Poll T. Severe sepsis and septic shock. N. Engl. J. Med. 2013;369:840–851. doi: 10.1056/NEJMra1208623. - DOI - PubMed
    1. Levy M.M., Artigas A., Phillips G.S., Rhodes A., Beale R., Osbor T., Vincent J.-L., Townsend S., Lemeshow S., Dellinger R.P. Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: A prospective cohort study. Lancet Infect. Dis. 2012;12:919–924. doi: 10.1016/S1473-3099(12)70239-6. - DOI - PubMed
    1. Dellinger R.P., Levy M.M., Rhodes A., Annane D., Gerlach H., Opal S.M., Sevransky J.E., Sprung C.L., Douglas I.S., Jaeschke R., et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Intensive Care Med. 2013;41:580–637. doi: 10.1097/CCM.0b013e31827e83af. - DOI - PubMed

Publication types